[HTML][HTML] Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer
T Zeller, IA Münnich, R Windisch, P Hilger… - Frontiers in …, 2023 - frontiersin.org
Immune checkpoint blockade is a compelling approach in tumor immunotherapy. Blocking
inhibitory pathways in T cells has demonstrated clinical efficacy in different types of cancer …
inhibitory pathways in T cells has demonstrated clinical efficacy in different types of cancer …
Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
Background CD38 has been established as an important therapeutic target for multiple
myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and …
myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and …
CD47 promotes peripheral T cell survival by preventing dendritic cell–mediated T cell necroptosis
S Komori, Y Saito, T Nishimura… - Proceedings of the …, 2023 - National Acad Sciences
Conventional dendritic cells (cDCs) are required for peripheral T cell homeostasis in
lymphoid organs, but the molecular mechanism underlying this requirement has remained …
lymphoid organs, but the molecular mechanism underlying this requirement has remained …
[HTML][HTML] SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the “don't eat me” signal and activating …
J Yu, S Li, D Chen, D Liu, H Guo, C Yang… - Journal of Hematology & …, 2022 - Springer
A novel recombinant SIRPα-Fc fusion protein, IMM01, was constructed and produced using
an in-house developed CHO-K1 cell expression system, and the anti-tumor mechanism of …
an in-house developed CHO-K1 cell expression system, and the anti-tumor mechanism of …
[HTML][HTML] Deciphering the role of QPCTL in glioma progression and cancer immunotherapy
Background Glioma is the most lethal and most aggressive brain cancer, and currently there
is no effective treatment. Cancer immunotherapy is an advanced therapy by manipulating …
is no effective treatment. Cancer immunotherapy is an advanced therapy by manipulating …
[HTML][HTML] Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages
T Zeller, S Lutz, IA Münnich, R Windisch… - Frontiers in …, 2022 - frontiersin.org
Antibody-dependent cellular phagocytosis (ADCP) by macrophages, an important effector
function of tumor targeting antibodies, is hampered by 'Don´ t Eat Me!'signals such as CD47 …
function of tumor targeting antibodies, is hampered by 'Don´ t Eat Me!'signals such as CD47 …
[HTML][HTML] Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab
N Baumann, C Arndt, J Petersen, M Lustig… - Frontiers in …, 2022 - frontiersin.org
Antibody-based immunotherapy is increasingly employed to treat acute lymphoblastic
leukemia (ALL) patients. Many T-ALL cells express CD38 on their surface, which can be …
leukemia (ALL) patients. Many T-ALL cells express CD38 on their surface, which can be …
Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis
F Vogiatzi, J Heymann, K Müller, D Winterberg… - Blood …, 2022 - ashpublications.org
Immunotherapy has evolved as a powerful tool for the treatment of B-cell malignancies, and
patient outcomes have improved by combining therapeutic antibodies with conventional …
patient outcomes have improved by combining therapeutic antibodies with conventional …
[HTML][HTML] A bright horizon: immunotherapy for pediatric T-cell Malignancies
H Newman, DT Teachey - International Journal of Molecular Sciences, 2022 - mdpi.com
Immunotherapy has transformed the treatment of hematologic malignancies in the past two
decades. The treatment of acute lymphoblastic leukemia (ALL), in particular, has been …
decades. The treatment of acute lymphoblastic leukemia (ALL), in particular, has been …
[HTML][HTML] Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia
E Brivio, F Bautista, CM Zwaan - Haematologica, 2024 - ncbi.nlm.nih.gov
The treatment of childhood acute lymphoblastic leukemia (ALL) has reached overall survival
rates exceeding 90%. The present and future challenges are to cure the remainder of …
rates exceeding 90%. The present and future challenges are to cure the remainder of …